نتایج جستجو برای: high dose cytarabine
تعداد نتایج: 2292508 فیلتر نتایج به سال:
Psoriasis is a common chronic inflammatory skin disease. The most common form of psoriasis is characterized by sharply demarcated, scaly, erythematous plaques. The face is an unusual site for psoriasis. Herein, we report a 43-year-old woman with facial psoriasis that was developed after remission–induction chemotherapy for acute leukemia with high dose cytarabine/daunorubicin.
PURPOSE Intensification by high-dose cytarabine in postremission or induction therapy and prolonged maintenance are established strategies to improve the outcome in patients with acute myeloid leukemia (AML). Whether additional intensification can add to this effect has not yet been determined. PATIENTS AND METHODS A total of 1,770 patients (age 16 to 85 years) with de novo or secondary AML o...
BACKGROUND Acute pancreatitis in acute myeloid leukemia (AML) has been rarely associated with cytarabine therapy. This report attempts to characterize this toxicity. PATIENTS AND METHODS Criteria for pancreatitis was prospectively defined. Seven patients with pancreatitis were identified from an AML database and a clinical study at two tertiary care centers (n = 134). Their records were retro...
BACKGROUND Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy compared with high-dose methotrexate alone is unproven. We assessed the effect of adding high-dose cytarabine to methotrexate in patients with newly diagnosed primary CNS lymphoma. METHODS This open, randomised, phase 2 trial was undertaken in 24...
BACKGROUND High-dose cytarabine has been associated with a high frequency of viridans group streptococcal (VGS) bacteraemia. VGS bacteraemia causes considerable morbidity and mortality. The Nordic Society of Paediatric Haematology and Oncology (NOPHO)-AML protocols use higher cumulated doses of cytarabine and more chemotherapy series (n = 6) than other protocols with the potential increased ris...
The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase chronic myeloid leukemia (CML). Patients received 2 cycles of intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1-7) in conjunction with imatinib (200 mg, 400 mg, 600 mg, or 800 mg), according to predefined, successive dose levels. All ...
We present a case of cytarabine-induced syndrome inappropriate secretion antidiuretic hormone (SIADH), rare manifestation and complication, which based on review the medical literature was reported only in one prior report. It involves 74-year-old male with acute myeloid leukemia who developed asymptomatic hyponatremia during three cycles consolidation chemotherapy high-dose cytarabine (HiDAC)....
Abstract Cytarabine neurotoxicity is well-documented, typically occurring after intrathecal treatment or a cumulative systemic dose of 36 g/m2. Encephalopathy, myelopathy, and acute cerebellar syndrome have all been described, with risk factors including advanced age renal dysfunction. Here, we report case single cycle intravenous cytarabine 3 This 65 year old man history chronic kidney disease...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید